Anemia and Kidney Disease 2019: May Special Section

5ackf1.jpgIn this month’s edition of ASN Kidney News, we reintroduce the topic of the management of anemia in CKD and ESKD. Depending on your vintage as nephrologists, these articles may serve as either a review or an introduction to what we have learned and experienced in this field. From the early heady days following the introduction of rEPO offering a “solution” to the nightmare of managing anemia with blood transfusions or anabolic steroids to the reality that “too much of a good thing” has consequences, we follow the journey of the clinical trials and science that now take us into a new era.

Phase 2 clinical trials with HIFs have suggested that they may present a more physiologic approach to anemia management, offering an effective oral agent that mobilizes iron and, at least to this point, has no serious short-term safety signals.

Drs. Coyne’s and Szczech’s review of the PIVOTAL trial helps clarify many outstanding questions about the safety and efficacy of iron in anemia management.

We have learned much, but there is more to learn; new questions, ideas, and opportunities will arise. We hope this series of articles engages and educates you on this topic and that you will help shape the future of anemia management.

—Robert Provenzano, MD, FACP, FASN and Edgar Lerma, MD, FASN, Editors



For further reading, please see the full Kidney News May issue.

Category:
Subcategory:
Body:

5ackf1.jpgIn this month’s edition of ASN Kidney News, we reintroduce the topic of the management of anemia in CKD and ESKD. Depending on your vintage as nephrologists, these articles may serve as either a review or an introduction to what we have learned and experienced in this field. From the early heady days following the introduction of rEPO offering a “solution” to the nightmare of managing anemia with blood transfusions or anabolic steroids to the reality that “too much of a good thing” has consequences, we follow the journey of the clinical trials and science that now take us into a new era.

Phase 2 clinical trials with HIFs have suggested that they may present a more physiologic approach to anemia management, offering an effective oral agent that mobilizes iron and, at least to this point, has no serious short-term safety signals.

Drs. Coyne’s and Szczech’s review of the PIVOTAL trial helps clarify many outstanding questions about the safety and efficacy of iron in anemia management.

We have learned much, but there is more to learn; new questions, ideas, and opportunities will arise. We hope this series of articles engages and educates you on this topic and that you will help shape the future of anemia management.

—Robert Provenzano, MD, FACP, FASN and Edgar Lerma, MD, FASN, Editors



For further reading, please see the full Kidney News May issue.

Date:
Monday, May 6, 2019